Innovation Leads the Future: MingYi ZhiZao Launches High-Throughput Oligo Synthesis Service

In the era of rapid development in life sciences and precision medicine, technological breakthroughs are continuously driving industrial innovation. After years of dedicated research and development,ME InstrumentsAchieved breakthroughs in DNA synthesis technology through continuous innovation capabilities,Officially Launching the Next-Generation High-Throughput Oligo Synthesis Service.This not only marks a qualitative leap for ME Instruments in the field of life science technology, but also serves as a profound tribute to sustainable development within the life sciences sector.

The ME Instruments team is dedicated to translating the latest scientific achievements into practical applications through a professional, focused, and precision-driven R&D approach. This synthesis platform employs internationally leading technologies combined with precision instrument manufacturing processes to ensure high standards and superior product quality. Years of technological accumulation have granted us an unparalleled advantage in the field of high-throughput synthesis.

The newly launched high-throughput oligonucleotide (Oligo) synthesis service is capable of synthesizing sequences up to 180 nucleotides in length, with a single synthesis run yielding up to 1.2 million oligonucleotides.

ME Instruments provides end-to-end services from customized requirements to delivery, ensuring that each customer’s needs are met to the greatest extent. To meet customers’ delivery timelines, we offer a 48-hour synthesis service, thereby shortening their R&D and production cycles and enhancing their competitiveness in the market.

 Figure 1. High-Throughput Oligo Synthesis Workflow

● High synthesis efficiency: Millions of sequences can be synthesized in a single run, significantly reducing costs.

● High Accuracy: Advanced synthesis and purification technologies ensure product quality.

● High Flexibility: Supports customized customer requirements.

● High Stability: The synthesis platform undergoes rigorous quality control to ensure product stability and reliability.

1. The oligonucleotide pool achieves complete coverage of the target region with highly uniform characteristics, and an error rate as low as 0.002.

Figure 2. Quality Control of Oligonucleotide Pools

Figures A–C present quality control data for an oligonucleotide pool comprising 3,000 oligos, each with a synthesized length of 135 nt. The synthesized oligonucleotide pool was amplified and subsequently subjected to high-throughput sequencing analysis. A. Coverage abundance of the 3,000 sequences; B. Uniformity of the target sequences; C. Synthesis error rate of the target sequences. Figure D shows quality control data for an oligonucleotide pool containing 2,700 oligos, each with a synthesized length of 140 nt, which exhibited high uniformity across different GC content regions after amplification.

2. Hybridization capture using synthetic probes yielded highly uniform results.

 Figure 3. Performance of the Synthetic Panel

42.5 kb and 2.6 Mb panels were used for capture, with data demonstrating high uniformity across different GC regions.

To meet customer demands, ME Instruments’ new generation of high-throughput oligo synthesis products is now available for pre-order. We look forward to partnering with you to jointly advance scientific research and healthcare. Pre-order now to enjoy priority service and exclusive offers.

In a fiercely competitive market environment, ME Instruments remains driven by technological innovation, superior quality, and premium service, undaunted by any challenge. The ME Instruments team will continue to pursue excellence, forging ahead in an ever-evolving marketplace.

ME Instruments is committed to being your reliable partner on the path of corporate development. Feel free to consult us at any time; we look forward to working with you for mutual progress.

Company | ME Instruments Inc.

Website | www.me-itech.com

Email | mingyi@me-itech.com

Address | 1F, Building F, International Pharmaceutical Innovation Industrial Park, No. 28 Yuehu Road, Economic and Technological Development Zone, Lianyungang Area, China (Jiangsu) Pilot Free Trade Zone; Room 321, Factory Building No. 2, Huahan Technology Industrial Park, No. 19 Lanjin 4th Road, Heping Community, Pingshan Subdistrict, Pingshan District, Shenzhen

Phone | 0755-28336314
Mobile | 132 6315 0689